Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine and Busulfan in Hematologic Malignancies
NCT00506857Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2003
- Primary completion
- Aug 2011
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan and fludarabine in hematologic malignancy, chronic myeloid leukemia (CML), acute leukemia and 3 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 month. Started Nov 2003; status: completed.
02
Drugs
busulfanfludarabine
03
Conditions
hematologic malignancychronic myeloid leukemia (CML)acute leukemiamyelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT00506857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506857.